Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
55.92
-0.53 (-0.94%)
Jul 21, 2025, 4:00 PM - Market closed
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $264.86M in the quarter ending March 31, 2025, with 35.22% growth. This brings the company's revenue in the last twelve months to $1.08B, up 25.65% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.08B
Revenue Growth
+25.65%
P/S Ratio
6.49
Revenue / Employee
$3,098,017
Employees
350
Market Cap
6.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HALO News
- 7 days ago - Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) - Seeking Alpha
- 21 days ago - Halozyme Therapeutics Added to Russell 1000® Index - PRNewsWire
- 4 weeks ago - Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire
- 7 weeks ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - PRNewsWire
- 2 months ago - Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat - Seeking Alpha
- 2 months ago - Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS - PRNewsWire